Main description:

This concise handbook provides an overview of incretin-based therapies and guidance for incorporating them into the treatment of type 2 diabetes. Chapters include landmark clinical trials and international treatment guidelines in order to update readers with all major advances in the field. An ideal resource for medical professionals that treat patients with type 2 diabetes in hospital and clinical settings.

Contents:

1. Introduction and disease overviewReferences
2. Incretin hormones as a target for therapyIncretin hormone physiology The incretin-producing cellGIP and GLP-1 actionMeasurement of the incretin hormonesIncretin action in healthy individualsIncretin action in patients with type 2 diabetesTherapeutics applicationReferences
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of EndocrinologyAmerican Diabetes Association /European Association for the Study of DiabetesInternational Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapiesDPP-4 inhibitorsReferences